Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.43 |
| ▸ | DRD1 | P21728 | 4/20 | 0.43 |
| ▸ | DRD3 | P35462 | 4/20 | 0.43 |
| ▸ | DRD5 | P21918 | 3/20 | 0.43 |
| ▸ | ESR1 | P03372 | 8/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796118 | 0.96 | ESR1 (0.42) | DRD2DRD1DRD3DRD5ESR1 | |
| SCHEMBL6799175 | 0.91 | DRD1 (0.47) | DRD2DRD1DRD3DRD5ESR1 | |
| SCHEMBL6801258 | 0.91 | DRD1 (0.47) | DRD2DRD1DRD3DRD5ESR1 | |
| SCHEMBL31280223 | 0.89 | ESR1 (0.41) | DRD2DRD1DRD3DRD5ESR1 | |
| SCHEMBL630543 | 0.87 | ESR1 (0.40) | DRD2DRD1DRD3DRD5ESR1 | |
| SCHEMBL19484850 | 0.87 | ESR1 (0.40) | DRD2DRD1DRD3DRD5ESR1 | |
| SCHEMBL6799659 | 0.85 | DRD2 (0.45) | DRD2DRD1DRD3DRD5ESR1 | |
| SCHEMBL31541237 | 0.84 | ESR2 (0.38) | DRD2DRD1DRD3DRD5ESR1 | |
| SCHEMBL19460598 | 0.83 | ESR1 (0.40) | DRD2DRD1DRD3DRD5ESR1 | |
| SCHEMBL6794599 | 0.79 | ESR2 (0.49) | DRD2DRD1DRD3DRD5ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | MERCK & CO., INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | ESRRA, ESRRB, FSHR | DRD2 2105/4885DRD1 2636/4885DRD3 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.